Novozymes A/S

CPSE:NSIS B Stock Report

Market Cap: DKK 209.9b

Novozymes Future Growth

Future criteria checks 3/6

Novozymes is forecast to grow earnings and revenue by 13.7% and 6.6% per annum respectively. EPS is expected to grow by 14.1% per annum. Return on equity is forecast to be 7.9% in 3 years.

Key information

13.7%

Earnings growth rate

14.06%

EPS growth rate

Chemicals earnings growth14.5%
Revenue growth rate6.6%
Future return on equity7.88%
Analyst coverage

Good

Last updated21 Aug 2026

Recent future growth updates

Recent updates

Narrative Update • Aug 10

NSIS B: Consumer Health Probiotics Expansion Will Support Higher Multiple Potential

The analyst fair value estimate for Novozymes has increased from DKK 520 to DKK 540, as analysts cite a series of higher Street price targets in the DKK 460 to DKK 552 range and improving views on the company following recent rating upgrades. Analyst Commentary on Novozymes Recent research on Novozymes, through the merged Novonesis entity, points to a more constructive tone from several bullish analysts.
Narrative Update • Jul 24

NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Higher Multiple Potential

The analyst price target for Novozymes has been reset to DKK 520, with analysts pointing to updated assumptions on growth, profitability and valuation multiples as the main drivers of the change. Analyst Commentary Recent Street research on Novozymes, now part of Novonesis, shows a series of constructive shifts in sentiment, with several firms revisiting their assumptions on valuation, execution and growth.
Narrative Update • Jul 10

NSIS B: Fair Outlook Will Rely On Probiotic Expansion In China

The analyst fair value estimate for Novozymes has been raised from DKK 380 to DKK 400, reflecting a series of higher Street price targets from multiple firms as analysts point to updated views on growth, margins and valuation for Novonesis. Analyst Commentary Recent Street research on Novozymes and Novonesis highlights a mix of optimism on long term potential and caution around execution and valuation risk.
Narrative Update • Jun 26

NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Premium Multiple

Analysts have nudged the fair value estimate for Novozymes (Novonesis) slightly lower to DKK 548.58 from about DKK 560, reflecting a blend of trimmed Street price targets around DKK 552 and DKK 460, as well as updated assumptions for revenue growth, profit margins and a more conservative future P/E of 34x. Analyst Commentary Recent Street research on Novozymes reflects a mix of fine tuning on price targets and ratings, with bullish analysts focusing on the company’s positioning in consumer ingredients and its ability to support premium valuation metrics.
Analysis Article • Jun 22

Novozymes (CPSE:NSIS B) Stock Could Be 31% Below Fair Value After UndoAge Deal

UndoAge partnership puts Novozymes (CPSE:NSIS B) in focus The new Memorandum of Understanding between UndoAge and Novonesis to co develop probiotics and postbiotics for the Chinese consumer health market puts fresh attention on Novozymes stock for investors tracking microbiome related opportunities. See our latest analysis for Novozymes. At a share price of DKK394.2, Novozymes has seen momentum build recently, with a 30 day share price return of 5.40% and a 90 day gain of 12.44%, even as the...

Earnings and Revenue Growth Forecasts

CPSE:NSIS B - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20285,1279639811,53313
12/31/20274,7848468271,40714
12/31/20264,4637297101,3929
6/30/20264,2976327691,318N/A
3/31/20264,1995977741,282N/A
12/31/20254,1585847511,222N/A
9/30/20254,1425477451,123N/A
6/30/20254,098565569918N/A
3/31/20254,058459586950N/A
12/31/20243,8343066601,020N/A
9/30/20243,471314634941N/A
6/30/20243,047283599891N/A
3/31/20242,636334422692N/A
12/31/20232,402406281557N/A
9/30/20232,390430169485N/A
6/30/20232,38246083436N/A
3/31/20232,39048783476N/A
12/31/20222,360494150539N/A
9/30/20222,268460206554N/A
6/30/20222,186418262539N/A
3/31/20222,090416337530N/A
12/31/20212,009423379546N/A
9/30/20211,958427461593N/A
6/30/20211,914409432564N/A
3/31/20211,883389443577N/A
12/31/20201,883380459585N/A
9/30/20201,920415442521N/A
6/30/20201,955405465536N/A
3/31/20201,968439N/A482N/A
12/31/20191,924422N/A428N/A
9/30/20191,923411N/A460N/A
6/30/20191,917434N/A505N/A
3/31/20191,922417N/A477N/A
12/31/20181,927432N/A493N/A
9/30/20181,924427N/A515N/A
6/30/20181,915429N/A490N/A
3/31/20181,920423N/A501N/A
12/31/20171,952419N/A546N/A
9/30/20171,958421N/A533N/A
6/30/20171,934412N/A522N/A
3/31/20171,919414N/A547N/A
12/31/20161,902410N/A517N/A
9/30/20161,864394N/A488N/A
6/30/20161,883394N/A437N/A
3/31/20161,883384N/A450N/A
12/31/20151,876378N/A447N/A
9/30/20151,840366N/A395N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NSIS B's forecast earnings growth (13.7% per year) is above the savings rate (2.1%).

Earnings vs Market: NSIS B's earnings (13.7% per year) are forecast to grow faster than the Danish market (7.2% per year).

High Growth Earnings: NSIS B's earnings are forecast to grow, but not significantly.

Revenue vs Market: NSIS B's revenue (6.6% per year) is forecast to grow faster than the Danish market (4% per year).

High Growth Revenue: NSIS B's revenue (6.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NSIS B's Return on Equity is forecast to be low in 3 years time (7.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/21 23:34
End of Day Share Price 2026/08/21 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novozymes A/S is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Cezara LozneanuBarclays
Alexander SloaneBarclays
Sebastian SatzBarclays